Literature DB >> 15834462

Criticality of pH for accurate fluorometric measurements of dipyridamole levels in biological fluids.

B Oshrine1, A Malinin, A Pokov, A Dragan, D Hanley, V Serebruany.   

Abstract

Extended release dipyridamole (DIP) is widely used in clinical practice as an Aggrenox formulation, which is proven to improve outcomes for secondary stroke prevention in patients after acute vascular events. However, presently established fluorometry techniques are not suitable for trace amount determinations, because of the variable background fluorescence. The authors sought to determine whether biological fluid pH is important for the serial measures of DIP levels in the animal experiments and in patients treated with Aggrenox after ischemic stroke. Post-stroke patient (n = 34) and mice (n = 25) samples were tested to determine DIP levels by established techniques with FluoroMax 3 spectrofluorometer. Both the absorption and emission spectra of DIP were affected by modifications in pH. Fluorescence of DIP was found to be maximal at a wavelength of 490 nm (excitation 420 nm) and the spectral pattern was independent of pH. The intensity of fluorescence, however, was drastically lower at low pH (at pH 2.6, fluorescence was 4% of intensity at pH 9.8). Background plasma fluorescence, however, was completely unaffected by changes in pH. Using these fluorometric characteristics, a regression model that facilitates the efficient and sensitive determination of DIP concentration in biological fluids was formulated. Exploiting pH-dependent characteristics of DIP versus serum fluorescence patterns permits a convenient mathematical model to determine DIP concentration. This relatively inexpensive and time-efficient procedure can quantify drug levels in human/animal plasma/serum, thereby directly determining the level of patient adherence to the prescribed drug regimen, be it in the context of clinical trials or compliance with the animal protocol. Copyright 2005 Prous Science. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15834462     DOI: 10.1358/mf.2005.27.2.876284

Source DB:  PubMed          Journal:  Methods Find Exp Clin Pharmacol        ISSN: 0379-0355


  3 in total

1.  Dipyridamole Treatment Prior to Stroke Onset: Examining Post-stroke Cerebral Circulation and Outcome in Rabbits.

Authors:  Christopher D d'Esterre; Kenneth M Tichauer; Richard I Aviv; Wolfgang Eisert; Ting-Yim Lee
Journal:  Transl Stroke Res       Date:  2011-01-11       Impact factor: 6.829

2.  Additive effects of statin and dipyridamole on cerebral blood flow and stroke protection.

Authors:  Hyung-Hwan Kim; Naoki Sawada; Guray Soydan; Ho-Seong Lee; Zhipeng Zhou; Seo-Kyoung Hwang; Christian Waeber; Michael A Moskowitz; James K Liao
Journal:  J Cereb Blood Flow Metab       Date:  2008-04-02       Impact factor: 6.200

3.  High-throughput screening for modulators of ACVR1 transcription: discovery of potential therapeutics for fibrodysplasia ossificans progressiva.

Authors:  Serena Cappato; Laura Tonachini; Francesca Giacopelli; Mario Tirone; Luis J V Galietta; Martina Sormani; Anna Giovenzana; Antonello E Spinelli; Barbara Canciani; Silvia Brunelli; Roberto Ravazzolo; Renata Bocciardi
Journal:  Dis Model Mech       Date:  2016-04-28       Impact factor: 5.758

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.